Sharon Robertson, MD
Gynecologic Oncology · Indianapolis, INNPI 1891939567
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,065 of the $1,584 with a category attached, or 67.2%. Intuitive Surgical accounts for 80.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $1,195, 9.8 times the $122 reported in 2019. That places this record below the midpoint for gynecologic oncology clinicians in IN, where the typical reported total is $1,688.
Across 12 payments — averaging $132.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- GSK$117
- Clovis Oncology, Inc.$105
- Eisai Inc.$36
- AbbVie$29
- AstraZeneca$17
Across 2 payments — averaging $22,728 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$45K
- Merck$456
What the payments were for
- Travel & lodging$51933%
- Food & beverage$1,06567%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $1,280 |
| GSK | 2 | $117 |
| Clovis Oncology, Inc. | 1 | $105 |
| Eisai Inc. | 1 | $36 |
| AbbVie | 1 | $29 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,125
- Rubraca$105
- JEMPERLI$103
How this compares
$1,584 in reported general payments places this provider in the 45th percentile of 26 gynecologic oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 25 | $1,094 |
| Megestrol Acetate | 25 | $1,080 |
| Dexamethasone | 18 | $385 |
| Tamoxifen Citrate | 15 | $351 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Indianapolis
- Jessica Parker MetterIndianapolis$6K
- Hilary HinshawIndianapolis$5K
- Lisa LandrumIndianapolis$4K
- James DunlopIndianapolis$3K
- Tina AyeniIndianapolis$2K
- James CripeIndianapolis$2K
- Michael MethodIndianapolis$2K
- Hubert FornalikIndianapolis$1K
- Sarah GoodrichIndianapolis$1K
- Megan BuechelIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.